TABLE I.
Demographic and clinical characteristics of study subjects*
| Tissue-based platform |
Blood-based platform |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All study subjects (n = 185) | All study subjects in tissue-based platform (n = 124) | Non-EG (n = 55) | Active EG (n =39) | P value | All study subjects in blood-based platform (n = 108) | Non-EG (n = 67) | Active EG (n =27) | P value | ||
| Demographics | ||||||||||
| Age at biopsy (years) | 15.2 (11.0 − 20.0) | 15.5 (11.2 − 20.5) | 14.2 (8.4 − 18.0) | 16.5 (12.3 − 21.2) | 0.06 | 15.4 (11.2 − 19.5) | 14.6 (10.5 − 19.1) | 17.7 (12.5 − 20.6) | 0.11 | |
| Pediatric subjects | 124 (67.0%) | 81 (65.3%) | 40 (72.7%) | 23 (59.0%) | 0.19 | 74 (68.5%) | 48 (71.6%) | 15 (55.6%) | 0.15 | |
| Gender | Male | 90 (48.6%) | 65 (52.4%) | 24 (43.6%) | 21 (53.8%) | 0.40 | 51 (47.2%) | 28 (41.8%) | 14 (51.9%) | 0.49 |
| Race | White | 169 (91.4%) | 111 (89.5%) | 52 (94.5%) | 34 (87.2%) | 0.27 | 100 (92.6%) | 65 (97.0%) | 24 (88.9%) | 0.14 |
| History of EGID | ||||||||||
| EG only | 22 (11.9%) | 22 (17.7%) | - | 12 (30.8%) | - | 14 (13.0%) | - | 8 (29.6%) | - | |
| EG and EoE | 47 (25.4%) | 46 (37.1%) | - | 27 (69.2%) | - | 20 (18.5%) | - | 16 (59.3%) | - | |
| EG and EC | 2 (1.1%) | 1 (0.8%) | - | - | - | 2 (1.9%) | - | 2 (7.4%) | - | |
| EG, EoE, and EC | 3 (1.6%) | 3 (2.4%) | - | - | - | 3 (2.8%) | - | 1 (3.7%) | - | |
| EoE only | 20 (10.8%) | 10 (8.1%) | 10 (18.2%) | - | 10 (9.3%) | 10 (14.9%) | - | - | ||
| Clinical symptoms at biopsy | ||||||||||
| Symptomatic (any) | 130 (70.3%) | 85 (68.6%) | 30 (54.6%) | 39 (100%) | < 0.01 | 90 (83.3%) | 53 (79.1%) | 27 (100%) | < 0.01 | |
| Abdominal pain | 91 (49.2%) | 52 (41.9%) | 19 (34.6%) | 22 (56.4%) | 0.04 | 66 (61.1%) | 41 (61.2%) | 18 (66.6%) | 0.62 | |
| Heartburn | 66 (35.7%) | 37 (29.8%) | 13 (23.6%) | 12 (30.8%) | 0.44 | 45 (44.4%) | 30 (44.8%) | 9 (33.3%) | 0.31 | |
| Nausea/vomit | 88 (47.6%) | 54 (43.6%) | 23 (41.8%) | 19 (48.7%) | 0.51 | 60 (55.6%) | 40 (59.7%) | 14 (51.9%) | 0.49 | |
| Other | 33 (17.8%) | 33 (26.6%) | 20 (36.4%) | 16 (41.0%) | 0.65 | 14 (13.0%) | 19 (28.4%) | 11 (40.7%) | 0.24 | |
| Atopic status | ||||||||||
| Atopy (any) | 129 (69.7%) | 84 (67.7%) | 36 (65.5%) | 31 (79.5%) | 0.17 | 76 (70.4%) | 51 (76.1%) | 19 (70.4%) | 0.61 | |
| Asthma | 74 (40.0%) | 49 (39.5%) | 14 (25.5%) | 19 (48.7%) | 0.03 | 40 (37.0%) | 25 (37.3%) | 11 (40.7%) | 0.82 | |
| Allergic rhinitis | 80 (43.2%) | 55 (44.4%) | 25 (45.5%) | 18 (46.2%) | 1.00 | 48 (44.4%) | 30 (44.8%) | 14 (51.9%) | 0.65 | |
| Eczema | 52 (28.1%) | 33 (26.6%) | 11 (20.0%) | 13 (33.3%) | 0.16 | 30 (27.8%) | 20 (29.9%) | 9 (33.3%) | 0.81 | |
| Food allergy | 60 (32.4%) | 58 (46.8%) | 12 (21.8%) | 28 (71.8%) | < 0.01 | 18 (16.7%) | 1 (1.5%) | 11 (40.7%) | < 0.01 | |
| Treatment at biopsy | ||||||||||
| Ongoing diet | 54 (29.2%) | 44 (35.5%) | 13 (23.6%) | 22 (56.4%) | < 0.01 | 29 (26.9%) | 10 (14.9%) | 13 (48.1%) | < 0.01 | |
| therapy | ||||||||||
| Proton pump | 93 (50.3%) | 48 (38.7%) | 19 (34.5%) | 19 (48.7%) | 0.29 | 67 (62.0%) | 48 (71.6%) | 15 (55.6%) | 0.15 | |
| inhibitor | ||||||||||
| Topical steroids | 50 (27.0%) | 49 (39.5%) | 13 (23.6%) | 19 (48.7%) | 0.03 | 19 (17.6%) | 0 (0%) | 12 (44.4%) | < 0.01 | |
| Systemic steroids | 10 (5.4%) | 8 (6.5%) | 0 (0%) | 5 (12.8%) | 0.01 | 6 (5.6%) | 0 (0%) | 2 (7.4%) | 0.08 | |
| Disease parameters in stomach | ||||||||||
| Peak eosinophil | 16 (10 − 65) | 16 (10 − 63) | 11 (6 − 15) | 124 (68 − 192) | < 0.01 | 56 (10 − 127) | 7 (5 − 9) | 123 (77 − 183) | < 0.01 | |
| counts | ||||||||||
| Average eosinophil | 11.8 (6.0 − 53.7) | 11.8 (5.9 − 51.1) | 6.6 (3.8 − 10.0) | 88.2 (61.2 − 142.6) | < 0.01 | 33.8 (5 − 77.2) | 4.3 (1.9 − 5.0) | 72.6 (62.0 − 128.6) | < 0.01 | |
| counts | ||||||||||
| Endoscopic | 0(0−3) | 0(0−3) | 0(0−0) | 4(0−7) | < 0.01 | 2(0−5) | 0(0−0) | 6(3−7) | < 0.01 | |
| severity | ||||||||||
| Histologic severity | 0.14 (0.09 − 0.35) | 0.14 (0.09 − 0.35) | 0.09 (0.05 − 0.14) | 0.41 (0.35 − 0.55) | < 0.01 | 0.35 (0.10 − 0.46) | 0.10 (0.06 − 0.10) | 0.35 (0.29 − 0.50) | < 0.01 | |
*
Data pertains to the time at pertains to the time at biopsy/blood procurement. Data are n (%) or median (IQR). EGID, eosinophilic gastrointestinal disorders; EG, eosinophilic gastritis; EoE, eosinophilic esophagitis; EC, eosinophilic colitis; EGDP, ophilic gastritis diagnostic panel.